Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Recently Diagnosed
Key facts
- Who runs it
- Sint Maartenskliniek
- Where
- Netherlands7 sites in 1 countryChoose a country to see its sites
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 114 people enrolled
- Started
- 1 Feb 2023
- Ended
- 29 Oct 2025
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Rituximab
- Placebo
- Record updated
- 3 February 2026
Who can take part
- Age
- 50 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Polymyalgia rheumatica diagnosis fulfilling the 2012 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria
- Diagnoses less than 12 weeks ago
- Glucocorticoid treatment less than 8 weeks and with dose equivalent of prednisolone ≤ 30 mg/day
- Informed consent
Who cannot take part
- treatment with systemic immunosuppressants (other than glucocorticoids) 3 months prior to inclusion
- (clinical) suspect concomitant giant cell arteritis or other rheumatic inflammatory diseases
- concomitant conditions that might significantly interfere with PMR pain or movement evaluation as judged by the investigator
- previous hypersensitivity for RTX or contra-indications to RTX
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Polymyalgia rheumatica (PMR) is prevalent among elderly. Untreated, it leads to major reduction in quality of life. Glucocorticoids are the cornerstone of treatment, but have drawbacks, warranting glucocorticoid sparing treatment. A proof of concept study on Rituximab (RTX) vs placebo showed efficacy in 48 vs 21%(p=0.049) in glucocorticoid free remission after 21 weeks (Marsman et al. 2021). Though promising, the short study duration and small sample size require further confirmation. Therefore a larger randomised controlled trial with longer follow up will be performed on RTX efficacy on glucocorticoid free remission in newly diagnosed PMR patients during glucocorticoid taper.
The 2 groups in the trial
- RituximabTreatment being tested
1000mg rituximab intravenously once
- PlaceboPlacebo, for comparison
0mg rituximab (placebo) intravenously once
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
- Official title
- Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica
- Publications
- Polymyalgia rheumatica and giant cell arteritis: diagnosis and management.Current opinion in rheumatology, 2025
- Record updated
- 3 February 2026